Mechanisms of deregulated response to hypoxia in sporadic amyotrophic lateral sclerosis: A clinical study;Mécanismes de dérégulation de la réponse à l'hypoxie dans la sclérose latérale amyotrophique

Revue Neurologique

Volumn 166, Issue 3, 2010, Pages 279-283

  Moreau, C ^a   Devos, D ^a   Gosset, P ^b   Brunaud Danel, V ^a   Tonnel, A B ^b   Lassalle, P ^b   Defebvre, L ^a   Destee A ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Amyotrophic lateral sclerosis; ANG; Deregulation; Hypoxia; PGE 2; VEGF

Indexed keywords

ANGIOPOIETIN 2; CYCLOOXYGENASE 2; ERYTHROPOIETIN; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

AMYOTROPHIC LATERAL SCLEROSIS; BRAIN FUNCTION; CARDIOVASCULAR RISK; CEREBROSPINAL FLUID; HUMAN; HYPOXEMIA; HYPOXIA; INFLAMMATION; LUNG FUNCTION; REOXYGENATION; REVIEW;

AMYOTROPHIC LATERAL SCLEROSIS; ANOXIA; BIOLOGICAL MARKERS; CELL HYPOXIA; HUMANS; INFLAMMATION; RISK FACTORS;

EID: 77949272233     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurol.2009.05.018     Document Type: Review

References (32)

1. Armon C., and Moses D. Linear estimates of rates of disease progression as predictors of survival in patients with ALS entering clinical trials. J Neurol Sci 160 Suppl. 1 (1998) S37-41
2. Arnulf I., Similowski T., Salachas F., et al. Sleep disorders and diaphragmatic function in patients with amyotrophic lateral sclerosis. Am J Respir Crit Care Med 161 (2000) 849-856
3. Bell E., Klimova T., Eusenbart J., Schumacker P., and Chandel P. Mitochondrial reactive oxygen species trigger hypoxia inducible factor dependant extension of the replicative life span during hypoxia. Mol Cell Biol 27 (2007) 737-745
4. Chavez J.C., Baranova O., Lin J., and Pichiule P. The transcriptional activator hypoxia inducible factor-2 (HIF-2/EPAS) regulates the oxygen dependent expression of erythropoietin in cortical astrocytes. J Neurosci 37 (2006) 9471-9481
5. Cronin S., Greenway M.J., Ennis S., Kieran D., Green A., Prehn J.H., et al. Elevated serum angiogenin levels in ALS. Neurology 67 (2006) 1833-1836
6. Danel-Brunaud V., Perez T., Just N., and Destée A. Surveillance et traitement des troubles respiratoires dans la SLA. Rev Neurol (Paris) 161 (2005) 480-485
7. Elman L.B., Siderowf A.D., and McCluskey L.F. Nocturnal oxymetry: utility in the repiratory management of amyotrophiclateral sclerosis. Am J Phys Med Rehabil 82 (2003) 866-870
8. Garbuzova-Davis S., Sanberg C.D., Kuzmin-Nichols N., et al. Human umbilical cord blood treatment in a mouse model of ALS: optimization of cell dose. PLoS One 3 (2008) e2494
9. Greenberg H., Ye X., Wilson D., et al. Chronic intermittent hypoxia activates nuclear factor κB in cardiovascular tissues in vivo. Biochem Biophys Res Commun 343 (2006) 591-596
10. Hukins C.A., and Hillman D.R. Daytime predictors of sleep hypoventilation in Duchenne muscular dystrophy. Am J Respir Crit Care Med 161 (2000) 166-170
11. Just N., Moreau C., Lassalle P., Gosset P., Perez T., Brunaud-Danel V., et al. High erythropoietin and low vascular endothelial growth factor levels in cerebrospinal fluid from hypoxemic ALS patients suggest an abnormal response to hypoxia. Neuromuscul Disord 17 2 (2007) 169-173 Epub 2006 (http://www.ncbi.nlm.nih.gov/pubmed/17142042?ordinalpos=2&itool=Entr ezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.P ubmed_RVDocSum)
12. Kong J., and Xu Z. Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophiclateral sclerosis in mice expressing mutant SOD. J Neurosci 18 (1998) 3241-3250
13. Lyall R.A., Donaldson N., Polkey M.I., et al. Respiratory muscle strength and ventilatory failure in amyotrophic lateral sclerosis. Brain 124 (2001) 2000-2013
14. 165 expression in retinal cells by hypoxia. Invest Ophthalmol Vis Sci 44 (2003) 4163-4170
15. Mandrioli J., Faglioni P., Merelli E., et al. The epidemiology of ALS in Modena, Italy. Neurology 60 (2003) 683-689
16. Moreau C., Devos D., Brunaud-Danel V., et al. Elevated levels of IL-6 in CSF from sporadic ALS patients: inflammation or hypoxia?. Neurology 65 (2005) 1958-1960
17. 165 expression in CSF to hypoxia in ALS patients. J Neurol Neurosurg Psychiatry 77 (2006) 255-257 (http://www.ncbi.nlm.nih.gov/pubmed/16421133?ordinalpos=3&itool=Entr ezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.P ubmed_RVDocSum)
18. Moreau C., Gosset P., Brunaud-Danel V., et al. CSF profiles of angiogenic and inflammatory factors depend on the respiratory status of ALS patients. Amyotroph Lateral Scler 10 (2009) 175-181
19. Murakami T., Nagai M., Miyazaki K., et al. Early decrease of mitochondrial DNA repair enzymes in spinal motor neurons of presymptomatic transgenic mice carrying a mutant SOD1 gene. Brain Res 1150 (2007) 182-189
20. Ono S., Hu J., Shimizu N., et al. Increased IL-6 of skin and serum in ALS. J Neurol Sci (2001) 27-34
21. Oosthuyse B., Moons L., Storkebaum E., et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 28 (2001) 131-138
22. Pichiule P., Chavez J.C., and LaManna J.C. Hypoxic regulation of Angiopoïetin-2 expression in endothelial cells. J Biol Chem 279 (2004) 12171-12180
23. Pinto A.C., Evangelista T., Carvalho M., et al. Respiratory assistance with a non invasive ventilator (BIPAP) in MND/ALS patients: survival rates in a controlled trial. J Neurol Sci 129 (1995) 19-26
24. Ryan S., Taylor C., and Nicholas W. Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnea syndrome. Circulation 112 (2005) 2660-2667
25. Ryan S., Taylor C.T., and McNicholas W.T. Predictors of elevated nuclear factor-kappaB-dependent genes in obstructive sleep apnea syndrome. Am J Respir Crit Care Med 174 (2006) 824-830
26. Sathasivam S. VEGF and ALS. Neurosci Res 62 (2008) 71-81
27. Schulz R., Hummel C., Heineman S., et al. Serum levels of VEGF are elevated in patients with obstructive sleep apnea and severe nighttime hypoxia. Am J Respir Crit Care Med 165 (2002) 67-70
28. Sekizawa T., Openshaw H., Ohbo K., et al. Cerebrospinal fluid IL-6 in ALS: immunological parameter and comparison with inflammatory and non-inflammatory central nervous system diseases. J Neurol Sci 154 (1998) 194-199
29. Sutedja N.A., Veldink J.H., Fisher K., et al. Lifetime occupation, education, smoking and risk of ALS. Neurology 69 (2007) 1508-1514
30. Veldink J.H., Kalmijn S., Groeneveld G.J., et al. Physical activity and the association with sporadic ALS. Neurology 64 (2005) 241-245
31. Wilms H., Rosenstiel P., Sievers J., Deuschl G., and Lucius R. Cerebrospinal fluid from patients with neurodegenerative and neuroinflammatory diseases: no evidence for rat glial activation in vitro. Neurosci Lett 314 (2001) 107-110
32. Zhong Z., Deane R., Ali Z., et al. ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration. Nat Neurosci 11 (2008) 420-422